In vitro study | ARQ 092 prevents membrane translocation of inactivated AKT, dephosphorylates membrane-bound active AKT, thus destroying AKT activity. In neutrophils and platelets, treatment with 50-500 nM ARQ092 will significantly prevent αMβ2 integrin function (neutrophils), reduces exposure and glycoprotein Ib/IX/V-mediated platelet aggregation by P-selectin. ARQ092 inhibits the proliferation of multiple tumor cell types and is most effective in leukemia, breast, endometrial and colon cancer cells. Furthermore, inhibition of ARQ 092 was more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations than in cancer cells containing wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT signaling pathway and specifically targets AKT to reduce the phosphorylation of GSK3α and GSK3β in mutant-containing cells. |